Evidence map›Paper›PMID 33477334›Full record

ReviewVaccines2021

Investigating the Interaction between Negative Strand RNA Viruses and Their Hosts for Enhanced Vaccine Development and Production.

Kostlend Mara, Meiling Dai, Aaron M Brice, Marina R Alexander, Leon Tribolet, Daniel S Layton, Andrew G D Bean

Open access · goldAbstract readReview
In one paragraph

Review in Vaccines, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.1field-weighted citation impact, top 61% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 2 citations in OpenAlex.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 1 institution in 1 country.

Kostlend MaraCSIRO Health & Biosecurity, Australian Centre for Disease Preparedness, Geelong, Vic 3220, Australia.ORCID 0000-0003-0055-6212
Meiling DaiCSIRO Health & Biosecurity, Australian Centre for Disease Preparedness, Geelong, Vic 3220, Australia.
Aaron M BriceCSIRO Health & Biosecurity, Australian Centre for Disease Preparedness, Geelong, Vic 3220, Australia.
Marina R AlexanderCSIRO Health & Biosecurity, Australian Centre for Disease Preparedness, Geelong, Vic 3220, Australia.ORCID 0000-0003-0745-7903
Leon TriboletCSIRO Health & Biosecurity, Australian Centre for Disease Preparedness, Geelong, Vic 3220, Australia.ORCID 0000-0002-2093-9678
Daniel S LaytonCSIRO Health & Biosecurity, Australian Centre for Disease Preparedness, Geelong, Vic 3220, Australia.
Andrew G D BeanCSIRO Health & Biosecurity, Australian Centre for Disease Preparedness, Geelong, Vic 3220, Australia.
Commonwealth Scientific and Industrial Research Organisation · AU

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The current pandemic has highlighted the ever-increasing risk of human to human spread of zoonotic pathogens. A number of medically-relevant zoonotic pathogens are negative-strand RNA viruses (NSVs). NSVs are derived from different virus families. Examples like Ebola are known for causing severe symptoms and high mortality rates. Some, like influenza, are known for their ease of person-to-person transmission and lack of pre-existing immunity, enabling rapid spread across many countries around the globe. Containment of outbreaks of NSVs can be difficult owing to their unpredictability and the absence of effective control measures, such as vaccines and antiviral therapeutics. In addition, there remains a lack of essential knowledge of the host-pathogen response that are induced by NSVs, particularly of the immune responses that provide protection. Vaccines are the most effective method for preventing infectious diseases. In fact, in the event of a pandemic, appropriate vaccine design and speed of vaccine supply is the most critical factor in protecting the population, as vaccination is the only sustainable defense. Vaccines need to be safe, efficient, and cost-effective, which is influenced by our understanding of the host-pathogen interface. Additionally, some of the major challenges of vaccines are the establishment of a long-lasting immunity offering cross protection to emerging strains. Although many NSVs are controlled through immunisations, for some, vaccine design has failed or efficacy has proven unreliable. The key behind designing a successful vaccine is understanding the host-pathogen interaction and the host immune response towards NSVs. In this paper, we review the recent research in vaccine design against NSVs and explore the immune responses induced by these viruses. The generation of a robust and integrated approach to development capability and vaccine manufacture can collaboratively support the management of outbreaking NSV disease health risks.

Indexed as

host immune responsehost–pathogen interactionNSV vaccinesRNA virusesvaccine designvaccine manufacturing

Identifiers

PMID33477334
PMCPMC7830660
OpenAlexW3123835122

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.